| Code | CSB-RA005508MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to IMAB027, targeting Claudin-6 (CLDN6), a tight junction protein that plays a critical role in cell-cell adhesion and epithelial barrier formation. CLDN6 exhibits highly restricted expression in normal adult tissues but becomes aberrantly re-expressed in various malignancies, including ovarian cancer, uterine cancer, testicular germ cell tumors, and certain lung cancers. This tumor-associated expression pattern makes CLDN6 an attractive target for cancer-specific immunotherapy and diagnostic applications.
IMAB027 is a chimeric IgG1 antibody that specifically recognizes CLDN6-expressing cells and has been extensively studied as a therapeutic candidate for CLDN6-positive cancers. This biosimilar antibody serves as a valuable research tool for investigating CLDN6 biology, evaluating tumor-associated antigen expression profiles, and supporting preclinical studies in oncology research. It enables researchers to explore CLDN6-mediated signaling pathways, assess antibody-dependent cellular cytotoxicity mechanisms, and validate CLDN6 as a biomarker in various cancer models.
There are currently no reviews for this product.